Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration
Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration
About this item
Full title
Author / Creator
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
AMD3100 (plerixafor, Mozobil®) was first identified as an anti-HIV agent specifically active against the T4-lymphotropic HIV strains, as it selectively blocked the CXCR4 receptor. Through interference with the interaction of CXCR4 with its natural ligand, SDF-1 (also named CXCL12), it also mobilized the CD34+stem cells from the bone marrow into the...
Alternative Titles
Full title
Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6379795
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6379795
Other Identifiers
ISSN
2040-2066,0956-3202
E-ISSN
2040-2066
DOI
10.1177/2040206619829382
